Vanucizumab ELISA Kit
Size: 96T
Catalogue Number: DT073038-96
Citations, Manuals and MSDS Available upon request.
Stability and Storage: The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
Detection Method: Colorimetric
Sample Type: Plasma, Serum
Assay Type: Quantitative
Sensitivity: 0.156 μg/ml
Range: 0.31-5 μg/mL
Recovery: 80-120%
Background: Vanucizumab (RG7221) is an experimental humanized monoclonal antibody (mAb) designed for the treatment of cancer. Vanucizumab is a bi-specific mAb composed of two different heavy chains and two different light chains. One arm of the antibody binds Angiopoietin-2 (Ang2) and the other is based on bevacizumab (Avastin), binding vascular endothelial growth factor A (VEGF-A). The antibody is designed to inhibit both VEGF-A and Ang2 simultaneously to offer superior clinical benefit compared to VEGF-A inhibition alone. This drug was developed by Genentech/Roche. On 12 Mar 2018, Roche completes a phase I trial in solid tumors (combination therapy, late-stage disease, metastatic disease, second-line therapy or greater) in Spain, France, and Belgium.
Shipping: 2-8 ℃
For Research Use Only.